At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
APRE Aprea Therapeutics, Inc.
Post-Mkt 12-12 19:43:55 EST
0.9349
-0.0101
-1.07%
盘后0.9720
+0.0371+3.97%
18:40 EST
High0.9780Low0.9349Vol84.16K
Open0.9500D1 Closing0.9450Amplitude4.56%
Mkt Cap5.90MTradable Cap4.29MTotal Shares6.31M
T/O80.36KT/O Rate1.83%Tradable Shares4.59M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Director Marc Duey Reports Acquisition of Common Shares in Aprea Therapeutics Inc
Reuters  ·  12-11 21:32
Director Marc Duey Reports Acquisition of Common Shares in Aprea Therapeutics Inc
Aprea Therapeutics CFO John P. Hamill Reports Acquisition of Common Shares
Reuters  ·  12-11 21:31
Aprea Therapeutics CFO John P. Hamill Reports Acquisition of Common Shares
Aprea Therapeutics Inc - Net Proceeds Expected to Fund Aprea Into 2027
THOMSON REUTERS  ·  12-09
Aprea Therapeutics Inc - Net Proceeds Expected to Fund Aprea Into 2027
Press Release: Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Dow Jones  ·  12-09
Press Release: Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Aprea Therapeutics Reports Continued Clinical Progress and Extends Cash Runway Into Q4 2026
Reuters  ·  11-12
Aprea Therapeutics Reports Continued Clinical Progress and Extends Cash Runway Into Q4 2026
Aprea Therapeutics Advances WEE1 Inhibitor APR-1051 in Phase 1 Trial for Hard-to-Treat Cancers
Reuters  ·  11-12
Aprea Therapeutics Advances WEE1 Inhibitor APR-1051 in Phase 1 Trial for Hard-to-Treat Cancers
Aprea Therapeutics Inc - Has Cash Runway Into Q4 2026
THOMSON REUTERS  ·  11-12
Aprea Therapeutics Inc - Has Cash Runway Into Q4 2026
Aprea Therapeutics Q3 Net Income USD -3 Million
THOMSON REUTERS  ·  11-12
Aprea Therapeutics Q3 Net Income USD -3 Million
BRIEF-Aprea Sees Early Activity in APR-1051 Wee1 Trial
Reuters  ·  10-24
BRIEF-Aprea Sees Early Activity in APR-1051 Wee1 Trial
Aprea Therapeutics Provides Clinical Update From Acesot-1051 Trial Showing Early Signals of Activity for Wee1 Kinase Inhibitor Apr-1051
THOMSON REUTERS  ·  10-24
Aprea Therapeutics Provides Clinical Update From Acesot-1051 Trial Showing Early Signals of Activity for Wee1 Kinase Inhibitor Apr-1051
Aprea Therapeutics Inc - No Dose Limiting Toxicities or Unexpected Safety Issues Reported
THOMSON REUTERS  ·  10-24
Aprea Therapeutics Inc - No Dose Limiting Toxicities or Unexpected Safety Issues Reported
Aprea Therapeutics Inc - Dose Escalation Continues With 150 Mg Cohort Enrollment
THOMSON REUTERS  ·  10-24
Aprea Therapeutics Inc - Dose Escalation Continues With 150 Mg Cohort Enrollment
Aprea Therapeutics Announces Presentations at Eortc-Nci-Aacr International Conference on Molecular Targets and Cancer Therapeutics
THOMSON REUTERS  ·  10-14
Aprea Therapeutics Announces Presentations at Eortc-Nci-Aacr International Conference on Molecular Targets and Cancer Therapeutics
Aprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Reuters  ·  08-12
Aprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aprea Therapeutics Reports Q2 2025 Results: Net Loss Narrows to $3.2M, EPS Improves to $0.53 from $0.58
Reuters  ·  08-12
Aprea Therapeutics Reports Q2 2025 Results: Net Loss Narrows to $3.2M, EPS Improves to $0.53 from $0.58
Aprea Therapeutics Q2 EPS USD -0.53
THOMSON REUTERS  ·  08-12
Aprea Therapeutics Q2 EPS USD -0.53
Aprea Therapeutics Inc expected to post a loss of 74 cents a share - Earnings Preview
Reuters  ·  08-09
Aprea Therapeutics Inc expected to post a loss of 74 cents a share - Earnings Preview
Aprea Says APR-1051 Shows Early Disease Control in HPV-Positive Head and Neck Cancer
MT Newswires Live  ·  06-25
Aprea Says APR-1051 Shows Early Disease Control in HPV-Positive Head and Neck Cancer
BRIEF-Aprea Reports Promising Early Data for WEE1 Inhibitor in HPV+ HNSCC with MD Anderson
Reuters  ·  06-25
BRIEF-Aprea Reports Promising Early Data for WEE1 Inhibitor in HPV+ HNSCC with MD Anderson

Introduction

Company Name.
Aprea Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Issue price:
--